GSK in Negotiations to Acquire Oncology Biotech Nuvalent for Over $9 Billion
GSK is negotiating to acquire Nuvalent for over $9 billion, marking its largest acquisition in over a decade, which could significantly enhance its oncology portfolio and address investor concerns about its drug pipeline.